| DC60180 |
BUN79398
Featured
|
BUN79398, also known as MRGPRX1 agonist 1, is a potent MRGPRX1 agonist (Mas-related G-protein-coupled receptor X1) (EC50 of 50 nM). BUN79398 is not only devoid of positively charged amidinium group but also with superior selectivity over opioid receptors. |
|
| DC60181 |
dCBP-1
Featured
|
dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drives MYC oncogene expression. As an efficient degrader of this unique class of acetyltransferases, dCBP-1 is a useful tool alongside domain inhibitors for dissecting the mechanism by which these factors coordinate enhancer activity in normal and diseased cells. |
|
| DC58005 |
Z-FF-FMK
Featured
|
Z-FF-FMK is a cell-permeant and irreversible inhibitor of cathepsin B and cathepsin L. |
|
| DC58006 |
Z-ASTD-FMK
Featured
|
Z-ASTD-FMK is a cell-permeant and irreversible inhibitor of endothelial monocyte-activated polypeptide II (EMAP II). |
|
| DC58007 |
GSK3685032
Featured
|
GSK-3685032(GSK 3685032) is a first-in-class, potent, non-nucleoside, reversible, selective inhibitor of DNMT1 with IC50 of 0.036 μM. GSK3685032 induces robust loss of DNA methylation, transcriptional activation and cancer cell growth inhibition in vitro. |
|
| DC58011 |
SKA-31
Featured
|
SKA-31 (Naphtho[1,2-d]thiazol-2-ylamine) is a potent activator of potassium channel with EC50 of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. |
|
| DC60182 |
Y 39983HCl
Featured
|
Y-39983, also known as Y-33075, is a potent and selective inhibitor of ROCK family with IC50 value of 3.6nM for ROCK. Y-39983 attenuates experimental autoimmune encephalomyelitis via inhibition of demyelination. Y-39983 downregulates RhoA/Rho-associated kinase expression during its promotion of axonal regeneration. Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. |
|
| DC60183 |
GR-103545 fumarate
Featured
|
GR-103545 is a reference and non-radio labeled agent. The radio-labeled 11C-GR103545 is a promising PET radiotracer for imaging the κ-OR.
|
|
| DC58030 |
R-Avanafil
Featured
|
Avanafil Impurity 8 |
|
| DC58033 |
Nox inhibitor 1
Featured
|
Novel Nox inhibitor，N2-(3,4-Dimethylphenyl)-6-((4-(p-tolyl)piperazin-1- yl)methyl)-1,3,5-triazine-2,4-diamine |
|
| DC47320 |
FRM-024
Featured
|
FRM-024 is a potent CNS-penetrant gamma secretase modulator for familial Alzheimer’s disease. |
|
| DC47321 |
Endovion (NS 3728)
Featured
|
Endovion (NS 3728, SCO-101) is an potent anion channel inhibitor that blocks the Volume Regulated Anion Channels (VRAC). |
|
| DC47351 |
ASP2453
Featured
|
ASP2453 is a potent, selective and covalent KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM. |
|
| DC47361 |
PZ703b
Featured
|
PZ703b is highly potent in killing BCL-XL dependent, BCL-2 dependent, and BCL-XL/BCL-2 dual-dependent cells in an E3 ligase (VHL)-dependent fashion. |
|
| DC47376 |
Rimtuzalcap
Featured
|
Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA). |
|
| DC47381 |
MOMIPP
Featured
|
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB). |
|
| DC47383 |
GSK251
Featured
|
GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode. |
|
| DC47388 |
PROTAC SHP2 degrader-1
Featured
|
PROTAC SHP2 degrader-1 is a potent and effective SHP2 degrader. PROTAC SHP2 degrader-1 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins and is also neddylation- and proteasome-dependent. |
|
| DC47398 |
MMV666810
Featured
|
MMV666810, a 2-aminopyrazine similar to MMV390048, is potent against asexual parasites at 5.94 nM, but against gametocytes, it has a 3.3-fold selectivity to late-stage gametocytes compared to earlier stages (early-stage gametocyte: IC50 603 ± 88 nM; late-stage gametocyte: IC50 179 ± 8 nM). |
|
| DC47399 |
MMV674850
Featured
|
MMV674850 is potent against asexual stage parasites at 2.7 and 4.5 nM and preferentially targets early-stage gametocytes (early-stage gametocyte: IC50 4.5 ± 3.6 nM; late-stage gametocyte: IC50 28.7 ± 0.2 nM). |
|
| DC47420 |
(S)-ErSO
Featured
|
(S)-ErSO is the dextrorotatory enantiomer of ErSO. (S)-ErSO is inactive in MCF-7 cells (from patent WO2020009958A1, compound (s)-105). |
|
| DC47422 |
p-SCN-Bn-DOTA
Featured
|
p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunotherapy of tumor. |
|
| DC47427 |
MK-4688
Featured
|
MK-4688 is an efficient inhibitor of the HDM2-p53 protein-protein interaction. |
|
| DC47434 |
DNDI-6148
Featured
|
DNDI-6148 acts principally through the inhibition of Leishmania cleavage and polyadenylation specificity factor (CPSF3) endonuclease for the treatment of visceral leishmaniasis (VL). |
|
| DC47467 |
UZH2
Featured
|
UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM. |
|
| DC47470 |
SBP-3264
Featured
|
SBP-3264 is a valuable chemical probe for understanding the roles of STK3 and STK4 in acute myeloid leukemia (AML). |
_1.gif)
|
| DC47483 |
RH-EDA
Featured
|
RH-EDA is a rhodamine-based turn-on fluorescent probe for detecting hydroxyl radicals in living systems. |
.gif)
|
| DC47507 |
BAY-091
Featured
|
BAY-091 is a novel potent and highly selective inhibitor of the kinase PIP4K2A. |
|
| DC47522 |
BI-6015
Featured
|
BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes. |
|
| DC47557 |
Aficamten(CK274)
Featured
|
Aficamten (CK-274) is a novel cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM). |
|
